Yuki Hamada, Kiyonori Tanoue, Yoshiaki Kita, Kan Tanabe, Kentaro Hokonohara, Masumi Wada, Yuto Hozaka, Hideyuki Oi, Chieri Nakayama, Michiyo Higashi, Takaaki Arigami, Shinichiro Mori, Takao Ohtsuka
PURPOSE: This study aims to investigate changes in the tumor immune environment of patients who underwent therapy with a vascular endothelial growth factor (VEGF) inhibitor for advanced colorectal cancer. METHODS: Patients ( n = 135) with T3 or T4 colorectal cancer were included in this retrospective study. They were classified as follows: patients who had not received preoperative treatment (UPFRONT group, n = 54), who had received FOLFOX as preoperative chemotherapy (FOLFOX group, n = 55), and who had undergone resection after combination FOLFOX and bevacizumab as unresectable colorectal cancer (B-MAB group, n = 26)...
March 29, 2023: Scandinavian Journal of Gastroenterology